Overview

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab